Stock GNRO GENEURO SA
Add to a list
To use this feature you must be a member
Log inSign up

Financials GeNeuro SA

Equities

GNRO

CH0308403085

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 03:00:07 2024-04-26 am EDT 		5-day change 1st Jan Change
1.43 EUR 0.00% Intraday chart for GeNeuro SA 0.00% +31.19%
Mar. 20 Geneuro SA Announces Appointments of Board of Directors CI
Feb. 02 GeNeuro: share price falls after private placement CF

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 50.18 53.94 57.33 78.83 37.3 42.32 42.32 -
Enterprise Value (EV) 1 41.41 51.36 50.49 74.25 31.71 55.32 50.22 77.22
P/E ratio -6.04 x -5.69 x -6.22 x -11.1 x -2.94 x -3.33 x 47.7 x -1.64 x
Yield - - - - - - - -
Capitalization / Revenue 6.72 x - - - - - 1.5 x -
EV / Revenue 5.55 x - - - - - 1.78 x -
EV / EBITDA -5.16 x - - - - -4.9 x 33.5 x -2.87 x
EV / FCF -2.36 x -5.17 x - - - -4.85 x - -2.86 x
FCF Yield -42.4% -19.4% - - - -20.6% - -35%
Price to Book 9.08 x -10.3 x 10.4 x - - -3.76 x -11.9 x -1.44 x
Nbr of stocks (in thousands) 14,589 14,579 20,476 22,204 24,868 29,596 29,596 -
Reference price 2 3.440 3.700 2.800 3.550 1.500 1.430 1.430 1.430
Announcement Date 4/1/19 4/7/20 4/6/21 4/4/22 4/5/23 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 7.463 - - - - - 28.2 -
EBITDA 1 -8.02 - - - - -11.3 1.5 -26.9
EBIT 1 -8.089 -8.99 -7.459 -6.366 -11.23 -11.3 1.5 -26.9
Operating Margin -108.38% - - - - - 5.32% -
Earnings before Tax (EBT) -8.328 -9.461 - - - - - -
Net income 1 -8.328 -9.461 -8.962 -6.818 -12.2 -11.3 1.1 -26.9
Net margin -111.59% - - - - - 3.9% -
EPS 2 -0.5700 -0.6500 -0.4500 -0.3200 -0.5100 -0.4300 0.0300 -0.8700
Free Cash Flow 1 -17.56 -9.943 - - - -11.4 - -27
FCF margin -235.29% - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 4/1/19 4/7/20 4/6/21 4/4/22 4/5/23 - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - 13 7.9 34.9
Net Cash position 1 8.78 2.58 6.84 4.57 5.59 - - -
Leverage (Debt/EBITDA) - - - - - -1.15 x 5.267 x -1.297 x
Free Cash Flow 1 -17.6 -9.94 - - - -11.4 - -27
ROE (net income / shareholders' equity) -89.5% - - -132% -387% - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 0.3800 -0.3600 0.2700 - - -0.3800 -0.1200 -0.9900
Cash Flow per Share 2 -1.200 -0.6800 -0.3600 -0.3200 -0.5500 -0.4500 0.0400 -0.9000
Capex 1 0.03 0.05 - - - 0.1 0.1 0.1
Capex / Sales 0.41% - - - - - 0.35% -
Announcement Date 4/1/19 4/7/20 4/6/21 4/4/22 4/5/23 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.43 EUR
Average target price
4 EUR
Spread / Average Target
+179.72%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GENEURO SA Stock GeNeuro SA
+31.19% 45.18M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GNRO Stock
  4. Financials GeNeuro SA